In the early phase of drug development for peptide APIs, speed to start Phase I is absolutely key. With our early phase development concept, including process and analytical development, we can strongly reduce the time to manufacturing Tox and first GMP material. Synchronized timelines and parallel workflows between drug substance and drug product within our PepCellerate™ platform allows to save time while reducing risks. A case study will be presented.
